Comparison 2. Subgroup analysis.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death (short‐term outcome, subgroup for time since stroke)	4	731	Risk Ratio (IV, Random, 95% CI)	0.45 [0.14, 1.46]
1.1 within 10 days	2	508	Risk Ratio (IV, Random, 95% CI)	0.25 [0.03, 2.28]
1.2 unknown	2	223	Risk Ratio (IV, Random, 95% CI)	0.56 [0.14, 2.31]
2 Death (short‐term outcome, subgroup for daily dose)	4	731	Risk Ratio (IV, Random, 95% CI)	0.45 [0.14, 1.46]
2.1 150 mg	2	223	Risk Ratio (IV, Random, 95% CI)	0.56 [0.14, 2.31]
2.2 200 mg	2	508	Risk Ratio (IV, Random, 95% CI)	0.25 [0.03, 2.28]
3 Improvement of neurological deficits (continuous, subgroup for time since stroke)	7	745	Std. Mean Difference (IV, Random, 95% CI)	‐0.98 [‐1.21, ‐0.75]
3.1 within 48 hours	3	391	Std. Mean Difference (IV, Random, 95% CI)	‐0.98 [‐1.28, ‐0.69]
3.2 within 72 hours	1	63	Std. Mean Difference (IV, Random, 95% CI)	‐0.64 [‐1.14, ‐0.13]
3.3 unknown	3	291	Std. Mean Difference (IV, Random, 95% CI)	‐1.09 [‐1.57, ‐0.62]
4 Improvement of neurological deficits (continuous, subgroup for delivery route)	7	745	Std. Mean Difference (IV, Random, 95% CI)	‐0.98 [‐1.21, ‐0.75]
4.1 intravenous	7	745	Std. Mean Difference (IV, Random, 95% CI)	‐0.98 [‐1.21, ‐0.75]
5 Improvement of neurological deficits (continuous, subgroup for daily dose)	7	745	Std. Mean Difference (IV, Random, 95% CI)	‐0.98 [‐1.21, ‐0.75]
5.1 100 mg daily	3	354	Std. Mean Difference (IV, Random, 95% CI)	‐1.14 [‐1.62, ‐0.67]
5.2 150 mg daily	1	143	Std. Mean Difference (IV, Random, 95% CI)	‐1.09 [‐1.44, ‐0.74]
5.3 200 mg	3	248	Std. Mean Difference (IV, Random, 95% CI)	‐0.77 [‐1.03, ‐0.51]
6 Improvement of neurological deficits (continuous, subgroup for treatment duration)	7	745	Std. Mean Difference (IV, Random, 95% CI)	‐0.98 [‐1.21, ‐0.75]
6.1 2 weeks	6	677	Std. Mean Difference (IV, Random, 95% CI)	‐0.92 [‐1.12, ‐0.72]
6.2 3 weeks	1	68	Std. Mean Difference (IV, Random, 95% CI)	‐1.60 [‐2.15, ‐1.05]
7 Improvement of neurological deficits (dichotomous, subgroup for time since stroke)	20	2374	Risk Ratio (IV, Random, 95% CI)	1.19 [1.14, 1.25]
7.1 within 6 hours	1	92	Risk Ratio (IV, Random, 95% CI)	1.15 [0.97, 1.37]
7.2 within 48 hours	2	306	Risk Ratio (IV, Random, 95% CI)	1.14 [1.04, 1.24]
7.3 within 72 hours	3	221	Risk Ratio (IV, Random, 95% CI)	1.10 [1.00, 1.20]
7.4 within 10 days	6	829	Risk Ratio (IV, Random, 95% CI)	1.21 [1.13, 1.30]
7.5 unknown	8	926	Risk Ratio (IV, Random, 95% CI)	1.27 [1.15, 1.39]
8 Improvement of neurological deficits (dichotomous, subgroup for delivery route)	20	2374	Risk Ratio (IV, Random, 95% CI)	1.19 [1.14, 1.24]
8.1 intravenous	18	2102	Risk Ratio (IV, Random, 95% CI)	1.16 [1.12, 1.20]
8.2 intravenous + oral	1	72	Risk Ratio (IV, Random, 95% CI)	1.42 [1.04, 1.94]
8.3 unknown	1	200	Risk Ratio (IV, Random, 95% CI)	1.83 [1.45, 2.30]
9 Improvement of neurological deficits (dichotomous, subgroup for daily dose)	20	2374	Risk Ratio (IV, Random, 95% CI)	1.19 [1.14, 1.24]
9.1 100 mg daily	4	413	Risk Ratio (IV, Random, 95% CI)	1.15 [1.03, 1.28]
9.2 150 mg daily	5	465	Risk Ratio (IV, Random, 95% CI)	1.16 [1.07, 1.25]
9.3 200 mg daily	10	1424	Risk Ratio (IV, Random, 95% CI)	1.22 [1.14, 1.31]
9.4 250 mg or more daily	1	72	Risk Ratio (IV, Random, 95% CI)	1.42 [1.04, 1.94]
10 Improvement of neurological deficits (dichotomous, subgroup for treatment duration)	20	2374	Risk Ratio (IV, Random, 95% CI)	1.19 [1.14, 1.24]
10.1 10 days	2	159	Risk Ratio (IV, Random, 95% CI)	1.07 [0.98, 1.17]
10.2 2 weeks	18	2215	Risk Ratio (IV, Random, 95% CI)	1.20 [1.15, 1.26]